43-Year-Old-Man Presents With Fatigue & Enlarged Lymph Nodes

July 9, 2014

By Cesar A. Moran, MD

Poll

43-year-old man presents with symptoms of fatigue and general malaise. Physical evaluation reveals the presence of enlarged neck lymph nodes. Biopsy of a lymph node is performed. What is your diagnosis?

A 43-year-old man presents with symptoms of fatigue and general malaise. Physical evaluation reveals the presence of enlarged neck lymph nodes. Biopsy of a lymph node is performed and is shown below.

What is your diagnosis?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos

Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.

Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.

Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.

At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.

Joseph C. Landolfi, DO, CPE, and Michelle Morrison, MPH, BSHA, RN, discuss how they can use their leadership roles to improve cancer care.

Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.

Related Content

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

Related Content

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

65 The Outcomes of Nipple Sparing Goldilocks Mastectomy in a Primarily Overweight and Obese Population

Allen Gee;Grace Oh;June Lee

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

FDA Grants THE001 Orphan Drug Designation for Soft Tissue Sarcomas

Roman Fabbricatore

The FDA designation follows an orphan drug designation granted by the European Medicines Agency for THE001 in patients with soft tissue sarcoma.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

67 Confocal Laser Scanning Microscopy (CLSM) for Intraoperative Histopathological Margin Assessment in Breast Conservation Surgery

Ken Weixing Ho;Nicholas Holford;Rathi Ramakrishnan;Patriek Jurrius;Sarah Pinder;Arnie Purushotham;Daniel Leff

TFOX Regimen Enhances Efficacy vs FOLFOX in HER2-Negative Gastric Cancer

Roman Fabbricatore

The safety profile of TFOX was consistent with data reported in previous studies, and no new safety signals were identified.

OncNursingNews.com

TargetedOnc.com

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.